Tissue engineering

Vesigen to Present at the 2024 Cell and Gene Meeting on the Med

Retrieved on: 
Wednesday, April 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, MED, Tissue engineering, Cell, Regenerative medicine, RNA, Gene editing, Therapy

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.
  • Virtual attendance is available which includes a livestream of Vesigen’s presentation and the ability to view all conference sessions on-demand.
  • Visit https://meetingonthemed.com/ for full information including registration.
  • Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a three-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

NextFlex Announces 2024 Fellows Awards for Five Outstanding Recipients

Retrieved on: 
Thursday, March 28, 2024
Hardware, IOT (Internet of Things), Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, Government Technology, Technology, Audio, Video, Defense, Military, Science, Telecommunications, Engineering, Research, Manufacturing USA, Tissue engineering, General Electric, USMC, Electrical engineering, Laser, Education, Madhu, Honeywell, Electronics, BD (company), AFRL, Plaque, NASA, STEM, SME, Miniaturization, Sigma, Printed electronics, Multimedia, Lighting, NRO, DARPA, Navy, Air Products, Management

NextFlex®, America's Hybrid Electronics Manufacturing Institute, presented the annual NextFlex Fellow Awards to five deserving individuals in recognition of their exceptional commitment to advanced manufacturing and the additive hybrid electronics member community.

Key Points: 
  • NextFlex®, America's Hybrid Electronics Manufacturing Institute, presented the annual NextFlex Fellow Awards to five deserving individuals in recognition of their exceptional commitment to advanced manufacturing and the additive hybrid electronics member community.
  • A NextFlex Fellow demonstrates leadership and subject matter expertise in support of the NextFlex mission.
  • View the full release here: https://www.businesswire.com/news/home/20240328483614/en/
    Left photo: 2024 Fellows Award recipients are presented with plaques by the NextFlex Co-Executive Directors.
  • These outstanding trailblazers exemplify what’s best about our member community as they help drive the NextFlex mission forward.

PLGA Market worth $321 Million by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 27, 2024
PLGA, Tissue engineering, Mitsui Chemicals, Health, Biomaterial, Biomedical Research, Investment, Pollution, Therapy, Administration

PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.

Key Points: 
  • PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.
  • This manufacturing technique involves injecting molten PLGA resin into a mold cavity under high pressure, where it solidifies to form the desired shape.
  • "North America captures the largest share in the PLGA market during the forecast period, in terms of value."
  • The PLGA market in North America stands as a vibrant and evolving landscape within the realm of biodegradable polymers.

PLGA Market worth $321 Million by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 27, 2024
PLGA, Tissue engineering, Mitsui Chemicals, Health, Biomaterial, Biomedical Research, Investment, Pollution, Therapy, Administration

PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.

Key Points: 
  • PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.
  • This manufacturing technique involves injecting molten PLGA resin into a mold cavity under high pressure, where it solidifies to form the desired shape.
  • "North America captures the largest share in the PLGA market during the forecast period, in terms of value."
  • The PLGA market in North America stands as a vibrant and evolving landscape within the realm of biodegradable polymers.

NASA, Health and Human Services Highlight Cancer Moonshot Progress

Retrieved on: 
Thursday, March 21, 2024
NASA Headquarters, Tissue engineering, Science, Federation, HHS, National Cancer Institute, Cancer, Death, Life, Cancer Breakthroughs 2020, Moon, NASA, Moonshot, Multimedia, Communications satellite

"In that microgravity environment, NASA is studying cancer growth—and the effect of cancer treatments— much faster than we can on Earth.

Key Points: 
  • "In that microgravity environment, NASA is studying cancer growth—and the effect of cancer treatments— much faster than we can on Earth.
  • I am grateful for President Biden's leadership as we continue to make moonshot after moonshot to end cancer as we know it."
  • As the second leading cause of death in the United States, the President and First Lady's Cancer Moonshot is a national effort to end cancer.
  • Learn more about Cancer Moonshot at:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nasa-health-and-human-services-...

Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical Trials

Retrieved on: 
Tuesday, March 19, 2024
Tissue engineering, Attention, Growth, SAN, Fascia, Tempo, Human, MAP, Regenerative medicine, Therapy, Safety, Innovation system

The funding will propel Tempo forward as it advances its revolutionary Microporous-Annealed-Particle (MAP) technology platform and takes its synthetic tissue scaffold candidates into clinical trials.

Key Points: 
  • The funding will propel Tempo forward as it advances its revolutionary Microporous-Annealed-Particle (MAP) technology platform and takes its synthetic tissue scaffold candidates into clinical trials.
  • In conjunction with the financing, Steven Sands of Galaxy Partners and a representative from JJDC will join the board.
  • With this financing, Tempo is entering into the first ever clinical trials of surgical scaffolds based on MAP technology.
  • "At Tempo Therapeutics, we are driven by a commitment to innovation and excellence in the field of regenerative medicine," said Westbrook Weaver, Founder and CEO of Tempo Therapeutics.

Stemson Therapeutics and Bosley Parent Company, Aderans, Sign Exclusive Hair Regeneration Licensing Deal

Retrieved on: 
Saturday, March 9, 2024
Health, Consumer, Genetics, Other Health, General Health, Men, Anxiety, Woman, Hair loss, Quality of life, Tissue engineering, Cell, Medicine, IPSC, Therapy, Patient, Research, Depression, Pharmaceutical industry

Stemson Therapeutics and Aderans Company , the parent company of Bosley ® and HAIRCLUB ®, today announced an agreement securing Stemson the exclusive global rights to research, develop and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology.

Key Points: 
  • Stemson Therapeutics and Aderans Company , the parent company of Bosley ® and HAIRCLUB ®, today announced an agreement securing Stemson the exclusive global rights to research, develop and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology.
  • Stemson will resume Aderans’ Phase 2 clinical stage cell therapy hair regeneration program, integrate the technology into its existing hair loss cell therapy development pipeline, and provide multiple products for patients experiencing hair loss.
  • Aderans’ proprietary hair regeneration platform is a cell therapy system that utilizes patient-derived hair and skin cells to durably rejuvenate shrinking hair follicles in patients with Androgenetic Alopecia by repopulating functional hair follicle cells into early-to-mid stage hair loss areas.
  • “Aderans’ early pioneering work in cell therapy for hair loss demonstrated to the field the potential for durable long lasting hair regeneration results by restoring functional hair cells and tissue.

Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Stem Cells, Pharmaceutical, Therapy, Incidence, Tissue engineering, EMA, Regenerative medicine, USD, FDA, Partnership, ATMP, Cell, CDMO, Gene therapy, COVID-19, Disorder, Patient, Clinical trial, CureVac, CureVac COVID-19 vaccine, Tissue, Research, Pharmaceutical industry

The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global advanced therapy medicinal products CDMO market is expected to reach USD 18.8 billion by 2030 and is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth.
  • Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
  • In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024
Health Technology, Data Management, Technology, Nanotechnology, Stem Cells, Biometrics, Medical Devices, Neurology, Genetics, Artificial Intelligence, Science, Biotechnology, Other Science, Health, Research, Paper, Therapy, Tissue engineering, Transcriptome, Gene editing, AI, Education, Substance abuse, Immunotherapy, Epigenome, Growth, Physiology, Interface, Cell, Vaccine, Behavior, Protein engineering, Biomedicine, University, Biomedical engineering, Guideline, Biological engineering, Patient, Genome, Johns Hopkins University, Genomics, Diagnosis, Tissue, DNA, Immune system, Brain, Medical imaging

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Retrieved on: 
Wednesday, February 14, 2024
Engineering, Regeneration, Regenerative medicine, Inflammation, North Carolina State University, Neovascularization, Infection, South Korea, WBC, Wilson College, Tissue engineering, KSBM, Decellularization, Congress, CELU, Trauma, Tissue, Development, Culture of Korea, LSC, Wound healing

FLORHAM PARK, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials (KSBM). The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”

Key Points: 
  • The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”
    The study described in the poster presentation investigated Celularity’s tri-layer decellularized, dehydrated human amniotic membrane technology product as a carrier of induced pluripotent stem cell derived-limbal stem cells (iPSC-LSC) which were investigated for the treatment of limbal stem cell deficiency (LSCD).
  • Limbal Stem Cell (LSC) transplant is a recognized method to restore the ocular surface in advanced stem cell deficient corneas.
  • Its Tissue Engineering Lab Team is particularly interested in corneal tissue engineering, focusing primarily on ocular surface regeneration.
  • The off-the-shelf availability of existing commercial tri-layer decellularized, dehydrated human amniotic membrane products, in combination with iPSC-LSCs, may improve patient access to LSCD treatment and the therapeutic management of LSCD.